Immune-Onc Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 18

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 22

Immune-Onc Therapeutics General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to develop novel therapies in immunology and oncology by targeting myeloid cells. The company has a focused platform approach and differentiated pipeline and has developed first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment, enabling patients to have access to new immunomodulatory.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 795 San Antonio Road
  • Palo Alto, CA 94303
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 795 San Antonio Road
  • Palo Alto, CA 94303
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immune-Onc Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Secondary Transaction - Private Completed Clinical Trials - Phase 2
9. Later Stage VC (Series B3) 05-Jan-2023 Completed Clinical Trials - Phase 1
8. Grant 20-Apr-2021 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 30-Mar-2021 Completed Clinical Trials - General
6. Grant 04-Aug-2020 Completed Pre-Clinical Trials
5. Grant 01-Aug-2020 Completed Pre-Clinical Trials
4. Debt - PPP 13-Apr-2020 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 18-Sep-2018 Completed Pre-Clinical Trials
2. Accelerator/Incubator 28-Jun-2017 $500K $7.5M Completed Product Development
1. Early Stage VC (Series A) 01-Sep-2016 $7M $7M Completed Product Development
To view Immune-Onc Therapeutics’s complete valuation and funding history, request access »

Immune-Onc Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B3
Series B2
Series B1
Series B 20,988,105 $0.000100 6% $1.58 $1.58 1x $1.58 17.37%
Series A 8,634,934 $0.000100 6% $0.81 $0.81 1x $0.81 7.15%
To view Immune-Onc Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Immune-Onc Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company intended to develop novel therapies in immunology and oncology by
Drug Discovery
Palo Alto, CA
18 As of 2025

Lexington, MA
 

Nahariya, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immune-Onc Therapeutics Competitors (35)

One of Immune-Onc Therapeutics’s 35 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agenus Formerly VC-backed Lexington, MA
Biond Biologics Venture Capital-Backed Nahariya, Israel
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
NextCure Formerly VC-backed Beltsville, MD
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 35 competitors. Get the full list »

Immune-Onc Therapeutics Patents

Immune-Onc Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250179173-A1 Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor Pending 17-Feb-2022
EP-4426740-A2 Novel anti-lilrb2 antibodies and derivative products Inactive 01-Nov-2021
AU-2021365142-A1 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020
AU-2021365142-A9 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020
CA-3198844-A1 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020 C07K16/2803
To view Immune-Onc Therapeutics’s complete patent history, request access »

Immune-Onc Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immune-Onc Therapeutics Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brightway Future Capital Venture Capital Minority
Proxima Ventures (China) Venture Capital Minority
Triwise Capital Venture Capital Minority
WuXi Biologics Corporation Minority
Leukemia & Lymphoma Society Not-For-Profit Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

Immune-Onc Therapeutics FAQs

  • When was Immune-Onc Therapeutics founded?

    Immune-Onc Therapeutics was founded in 2016.

  • Where is Immune-Onc Therapeutics headquartered?

    Immune-Onc Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of Immune-Onc Therapeutics?

    Immune-Onc Therapeutics has 18 total employees.

  • What industry is Immune-Onc Therapeutics in?

    Immune-Onc Therapeutics’s primary industry is Drug Discovery.

  • Is Immune-Onc Therapeutics a private or public company?

    Immune-Onc Therapeutics is a Private company.

  • What is Immune-Onc Therapeutics’s current revenue?

    The current revenue for Immune-Onc Therapeutics is .

  • How much funding has Immune-Onc Therapeutics raised over time?

    Immune-Onc Therapeutics has raised $138M.

  • Who are Immune-Onc Therapeutics’s investors?

    Brightway Future Capital, Proxima Ventures (China), Triwise Capital, WuXi Biologics, and Leukemia & Lymphoma Society are 5 of 22 investors who have invested in Immune-Onc Therapeutics.

  • Who are Immune-Onc Therapeutics’s competitors?

    Agenus, Biond Biologics, NGM Biopharmaceuticals, NextCure, and Adaptimmune Therapeutics are some of the 35 competitors of Immune-Onc Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »